

**Health Technology Clinical Committee**

**Date:** July 10, 2020  
**Time:** 9:00 – 10:00 a.m.  
**Location:** Webinar  
**Adopted:** November 20, 2020

Meeting materials and transcript are available on the [HTA website](#).

**HTCC Minutes**

**Members present:** John Bramhall, MD, PhD, Janna Friedly, MD; Chris Hearne, BSN, DNP, MPH; Conor Kleweno, MD; Laurie Mischley, ND, MPH, PhD; Sheila Rege, MD, MPH; Seth Schwartz, MD, MPH; Mika Sinanan, MD, PhD; Kevin Walsh, MD; Tony Yen, MD

**HTCC Formal Action**

- 1. Call to order:** Dr. Rege, chair, called the meeting to order; members present constituted a quorum.
- 2. HTA program updates:** Josh Morse, program director, presented HTCC meeting protocols and guidelines, and a high-level overview of the HTA program.
- 3. Previous meeting business:**

**June 12, 2020 meeting minutes:** Draft minutes reviewed. Motion made and seconded to approve the minutes as written.

Action: Ten committee members approved the June 12, 2020 meeting minutes.

**Tinnitus: non-invasive, non-pharmacologic treatments draft findings and decision:** Chair referred members to the draft findings and decision and called for further discussion. One comment was received on the draft determination language, proposing language to define the terminology used and clarify the procedures included in the determination in order to support implementation of the decision.

The committee considered the recommendations. Changes were made to clarify the intent of the determination: definitions of “tinnitus specific therapy” and “sound therapy” were added, as well as specific treatments that were reviewed by the committee under these categories.

Motion made and seconded to accept the findings and decision, as amended.

Action: Ten committee members approved the tinnitus: non-invasive, non-pharmacologic treatments findings and decision.

**Vagal nerve stimulation for epilepsy and depression draft findings and decision:** Chair referred members to the draft findings and decision and called for further discussion. Two comments were received on the draft decision. One commented on not having a clinical expert from psychiatry at the May 15 meeting. The other comment received included the request to clarify whether the determination applies to maintenance and repair of VNS devices already implanted for depression, and cited evidence including a

**Final**

recently published follow-up study. The committee discussed the comments. One additional line was inserted in the original draft to clarify that that scope of the determination does not apply to previously implanted devices. Motion made and seconded to accept the findings and decision, as amended.

Action: Ten committee members approved the vagal nerve stimulation for epilepsy and depression findings and decision.

**Stem cell therapy for musculoskeletal conditions draft findings and decision:** Chair referred members to the draft findings and decision and called for further discussion. No comments were received on the draft decision. The committee made no changes to the draft. Motion made and seconded to accept the findings and decision, as written.

Action: Ten committee members approved the stem cell therapy for musculoskeletal conditions findings and decision.

4. **HTA program work in progress:** Josh Morse, program director, provided an update on topic selection for the next review cycle, upcoming opportunities for public input, and planning for the HTCC retreat in September.
5. **Meeting adjourned**